Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.

British journal of cancer - 1 Dec 2020

Zhou Yitian, Dagli Hernandez Carolina, Lauschke Volker M

Abstract excerpt

BACKGROUND: Inter-individual differences in dihydropyrimidine dehydrogenase (DPYD encoding DPD) and thiopurine S-methyltransferase (TPMT) activity are important predictors for fluoropyrimidine and thiopurine toxicity. While several variants in these genes are known to decrease enzyme activities, many additional genetic variations with unclear functional consequences have been identified, complicating informed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Benchmarking
Share to Dihydrouracil Dehydrogenase (NADP)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ethnicity

Share to Exome Sequencing

Share to Genetic Variation

Share to Methyltransferases

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 32973300
DOI: 10.1038/s41416-020-01084-0
PMCID: PMC7722893

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.PMID 32973300Read ↗

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the LiteratureSemantic proximity Read ↗

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and OpportunitiesSemantic proximity Read ↗

Germline oncopharmacogenetics, a promising field in cancer therapy.Semantic proximity Read ↗

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping AssaysSemantic proximity Read ↗

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity Read ↗

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?Semantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.Semantic proximity Read ↗

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD VariantsSemantic proximity Read ↗

Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public healthSemantic proximity Read ↗

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol.Semantic proximity Read ↗

New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.